logo

Drug Development

Share SHARE

BillGates-CuringAlzheimers-111317.jpg Billionaire and Microsoft co-founder Bill Gates is making a personal investment of $50 million into the Dementia Discovery Fund, a venture capital fund that invests in projects and companies to develop treatments for the brain-wasting disease. The investment is not part of Gates' philanthropic Bill & Melinda Gates Foundation, which has focused primarily on infectious diseases.

Bristol-Myers Squibb Co. (BMY) announced the U.S. Food and Drug Administration (FDA) has expanded the indication for Sprycel or dasatinib tablets to include the treatment of children with Philadelphia chromosome-positive or Ph+ chronic myeloid leukemia or CML in chronic phase or CP. The approval for...

FDA-Approved-Oct-110717.jpg Yet another month has gone by, and it's time again to take a look-back at the new drugs that successfully crossed the therapeutics finish line. At the time of writing, 37 novel drugs were approved by the FDA for this year. This compares favorably with 22 novel drugs that were approved for the whole of 2016. Click here for the list of new drugs approved in October.

Alexion Pharmaceuticals Inc. (ALXN) said that the U.S. Food and Drug Administration has approved Soliris or eculizumab as a treatment for adult patients with generalized myasthenia gravis or gMG who are anti-acetylcholine receptor or AchR antibody-positive. In the Phase 3 REGAIN study and its ongoing...

Elililly-090717.jpg Eli Lilly and Co. (LLY) said Thursday that it plans to cut about 3,500 positions globally, as part of a streamlining plan. It expects to incur charges of about $1.2 billion pre-tax or $0.80 per share after-tax. It expects annualized savings of about $500 million that will begin to be realized in 2018.

Genentech, a member of the Roche Group (RHHBY), said that the U.S. Food and Drug Administration has accepted the company's supplemental Biologics License Application or sBLA and granted Priority Review for Gazyva or obinutuzumab in combination with chemotherapy followed by Gazyva alone for people with...

Mylan N.V. (MYL) said that its subsidiaries, Mylan Inc. and Mylan Specialty L.P., have signed an agreement with the U.S. Department of Justice and two relators finalizing the Medicaid drug rebate settlement that the Company announced on October 7, 2016 for $465 million. The settlement resolved...

Merck (MRK) said that it has accepted the external Data Monitoring Committee recommendation to pause new enrollment on KEYNOTE-183 and KEYNOTE-185, two studies exploring KEYTRUDA treatment in combination with other therapies in the blood cancer multiple myeloma. The company noted that the pause is...

Follow RTT